NEW YORK, Jan 17 - Cambridge Antibody Technology on Thursday said it intends to acquire Canada's Drug Royalty Corp. for C$126 million, or roughly $78 million, worth of CAT stock.

The UK-based biotech company said it decided to snag Drug Royalty Corp. in order to help bolster its own therapeutic antibody portfolio it's building through collaborations with pharma and other biotech firms.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.